Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

Abstract

Purpose Docetaxel is known to cause eye disorders. In this study, current status of eye disorders caused by docetaxel administration every 3 weeks in Japanese patients was examined. Methods This case-control study targeted patients who were newly administered docetaxel at the Kyoto Okamoto Memorial Hospital between 1 July 2015 and 30 June 2018. Eye disorder occurrence was defined as an event in which the pharmacist confirmed the symptoms in a patient interview and the ophthalmologist diagnosed the disorder. Results Of the 89 subjects, 7 (7.9%) had eye disorders. The symptoms were watering eyes (7.9%), a stye and eye discharge (2.2% each), corneal and conjunctival disorder, visual acuity reduction, and blepharedema (1.1% each). Four patients who presented with watering eyes, eye discharge, or corneal and conjunctival disorder showed improvement with the use of eye drops such as artificial tears. Two patients who presented with a stye showed improvement with the use of oral cefcapene. One patient with mild symptoms showed spontaneous improvement. However, one patient had irreversible visual acuity reduction. The multivariate logistic regression analysis revealed that a cumulative docetaxel dose of ≥300 mg/m2 (odds ratio: 15.50, 95% confidence interval: 1.37–175.00, p = 0.027) and concomitant cyclophosphamide use (odds ratio: 13.20, 95% confidence interval: 1.13–153.00, p = 0.039) were significant risk factors associated with eye disorders. Conclusion In conclusion, it was determined that docetaxel-related eye disorders might be influenced by the cumulative dose of docetaxel and concomitant cyclophosphamide use. In addition, relatively mild symptoms improved with medication.

Docetaxel for Breast Cancer Treatment-Side Effects on Ocular Surface, a Systematic Review

“…The median value of the cumulative dose was 291.0 (42.3-937.4). In previous trials, the multivariate regression analysis revealed that a higher cumulative dose was significantly associated with the presence of epiphora [14,27], and that a higher dose was significantly associated with the canalicular stenosis [14].…”

“…The inclusion criteria were met by 10 trials, from which one was excluded owinf to data selection biases. Accordingly, nine studies [7,14,25,[27][28][29][30][31][32] were evaluated quantitatively and qualitatively in our review (Table 1). From the eligible trials, a total of 456 women were included in the analysis.…”

“…All trials measured our primary outcome. Four of the trials selected [7,14,28,29] included subjects treated with both regimens, weekly and every 3 weeks docetaxel; the rest of the trials [25,27,[30][31][32] comprised women treated with a single regimen.…”

Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review

“…Docetaxel is a member of taxanes and inhibits mitosis in dividing cancer cells by preventing microtubule depolymerization and attenuating the effects of bcl-2 and bcl-xL expression [ 38 , 39 ]. It frequently causes canalicular and nasolacrimal duct obstruction, with resulting epiphora [ 40 , 41 ]. Docetaxel is secreted in the tear film, which results in canalicular chronic inflammation and is thought to be the cause of canalicular stenosis.…”

“…Epiphora may interfere with daily life activities and consists a troublesome symptom for patients. The use of lubricant eye drops may help wash out docetaxel and prevent dacryostenosis [ 40 , 41 ]. Docetaxel also rarely causes cystoid macular edema and erosive conjunctivitis [ 40 , 42 , 43 ].…”